Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 86   

Articles published

ARNA 1.47 -0.01 (-0.68%)
price chart
Price Target Update On Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
A number of investment brokers have recently updated their price targets on shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA).
Here's Why Arena Pharmaceuticals, Inc. Is Struggling Today
What: Arena Pharmaceuticals (NASDAQ:ARNA) was down as much as 12% today after its marketing partner Eisai released financial results for the first half of its fiscal year.
Needham Reiterates Hold on Arena Pharmaceuticals, Inc. (ARNA) Ahead of Earnings  Smarter Analyst
Biotech Beach: Needham Provides Updates on Gilead Sciences, Inc. (GILD), Arena ...
The biotechnology sector is always volatile, and the recent market sell-off only makes it more so. Consequently, Alan Carr of Needham notes that it is best to focus on “commercial-stage or regulatory-stage companies with substantial cash reserves” at ...
Arena Pharmaceuticals Inc. (ARNA) Jumps 9.66% on February 04
Arena Pharmaceuticals Inc. (ARNA) was among the biggest gainers on the Russell 2000 for Thursday February 04 as the stock popped 9.66% to $1.59, representing a gain of $0.14 per share.
Analyst Review Alert: Arena Pharmaceuticals, Inc. (ARNA)
Wall Street analysts have a much less favorable assessment of Arena Pharmaceuticals, Inc. (ARNA), with a mean rating of 2.7.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) PT & Analyst Recommendation Review  Uptick Analyst
Arena Pharmaceuticals, Inc. (ARNA) Earns Hold Rating from Needham & Company LLC
Needham & Company LLC reiterated their hold rating on shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) in a research note issued to investors on Wednesday, MarketBeat Ratings reports.
Zacks Investment Research Upgrades Arena Pharmaceuticals, Inc. (ARNA) to "Buy"
Arena Pharmaceuticals logo Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Tuesday, Market Beat.
Short Interest in Arena Pharmaceuticals, Inc. (ARNA) Decreases By 22.6%  Corvus Business Newswire
Arena Pharmaceuticals, Inc. (ARNA) Stock Rating Upgraded by Zacks Investment ...
Arena Pharmaceuticals logo Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday, ARN reports.
Boehringer Ingelheim, Arena Pharmaceuticals to research schizophrenia drug ...  Healio
Biotech Stock under consideration today: Arena Pharmaceuticals, Inc  iStreetWire
Arena Pharmaceuticals, Inc. (ARNA) Upgraded to Buy at Zacks Investment Research
Arena Pharmaceuticals logo Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Thursday, AnalystRatings.
Technical Analysis: Arena Pharmaceuticals, Inc.  CWRU Observer
Arena Pharmaceuticals, Inc. (ARNA) Stock Rating Lowered by Zacks Investment ...  Corvus Business Newswire
Zacks Investment Research Lowers Arena Pharmaceuticals, Inc. (ARNA) to Hold
Arena Pharmaceuticals logo Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday, MarketBeat.
Worth Watching Stocks: Arena Pharmaceuticals, Inc.  CWRU Observer
Arena Pharmaceuticals, Inc. Analyst Rating Update  Analyst Rating Reports